دورية أكاديمية
Dosimetric Features of Ultra-Hypofractionated Intensity Modulated Proton Therapy for Prostate Cancer.
| العنوان: | Dosimetric Features of Ultra-Hypofractionated Intensity Modulated Proton Therapy for Prostate Cancer. |
|---|---|
| المؤلفون: | Gao RW; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Ma J; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Pisansky TM; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Kruse JJ; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Stish BJ; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Kowalchuk RO; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., McMenomy BP; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Waddle MR; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Phillips RM; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Choo R; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Davis BJ; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA. |
| المصدر: | International journal of particle therapy [Int J Part Ther] 2024 Apr 24; Vol. 12, pp. 100015. Date of Electronic Publication: 2024 Apr 24 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101674108 Publication Model: eCollection Cited Medium: Internet ISSN: 2331-5180 (Electronic) Linking ISSN: 23315180 NLM ISO Abbreviation: Int J Part Ther Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2024- : [New York] : Elsevier Original Publication: Gainesville, FL : International Journal of Particle Therapy, [2014]- |
| مستخلص: | Purpose: To report clinical and dosimetric characteristics of 5-fraction stereotactic ablative radiotherapy (SABR) using intensity modulated proton therapy (IMPT) for localized prostate cancer. Materials and Methods: All patients receiving IMPT SABR from 2017 to 2021 for localized prostate cancer at our institution were included. Five fractions were delivered every other day to the prostate +/- seminal vesicles [clinical target volume (CTV)] with 3 mm/3% robustness. A 4-field arrangement with 2 anterior oblique and 2 opposed lateral beams was used in most patients (97%), and most (99%) had a retroprostatic hydrogel spacer. Results: A total of 534 patients with low (14%), favorable intermediate (45%), unfavorable intermediate (36%), high (4.0%), or very high-risk (0.6%) disease are evaluated. Prescription dose was 36.25 Gy (31%), 38 Gy (38%), or 40 Gy (31%) was prescribed. Median volume percentage of CTV receiving at least 100% of prescription dose [V100% (%)] was 100% [interquartile range: 99.99-100]. Rectum V50% (%), V80% (%), and V90% (%) were significantly lower in patients who had spacer, with a mean difference of -9.70%, -6.59%, and -4.42%, respectively, compared to those who did not have spacer. Femoral head dose was lower with a 4-field arrangement. Mean differences in left and right femoral head V40% (%) were -6.99% and -10.74%, respectively. Conclusion: We provide a large, novel report of patients treated with IMPT SABR for localized prostate cancer. Four-field IMPT with hydrogel spacer provides significant sparing of rectum and femoral heads without compromising target coverage. Competing Interests: The authors have no conflicts to disclose. (© 2024 The Author(s).) |
| References: | Lancet. 2019 Aug 3;394(10196):385-395. (PMID: 31227373) Radiother Oncol. 2014 Feb;110(2):291-7. (PMID: 24507766) Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):296-303. (PMID: 30191864) Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):235-41. (PMID: 21163587) Clin Transl Radiat Oncol. 2019 Aug 31;19:80-86. (PMID: 31650043) Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):596-602. (PMID: 24521677) Cancer. 2022 Nov 1;128(21):3815-3823. (PMID: 36070558) Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):408-18. (PMID: 22133626) Lancet Oncol. 2016 Aug;17(8):1047-1060. (PMID: 27339115) Cancer. 2014 Apr 1;120(7):1076-82. (PMID: 24382757) Phys Med Biol. 2021 Sep 09;66(18):. (PMID: 34433134) J Clin Oncol. 2016 Jul 10;34(20):2325-32. (PMID: 27044935) Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):744-51. (PMID: 17904306) Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):422-434. (PMID: 27084658) Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):713-722. (PMID: 31199994) Acta Oncol. 2012 Nov;51(8):963-74. (PMID: 22966812) Sci Rep. 2015 May 18;5:9850. (PMID: 25984967) Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1535-1543. (PMID: 27325476) CA Cancer J Clin. 2022 Jan;72(1):7-33. (PMID: 35020204) Prostate Cancer Prostatic Dis. 2020 Jun;23(2):349-355. (PMID: 31780782) JAMA Netw Open. 2020 Feb 5;3(2):e1920471. (PMID: 32022878) Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):616-22. (PMID: 19427561) Acta Oncol. 2017 Jul;56(7):963-970. (PMID: 28514929) Adv Radiat Oncol. 2020 Sep 28;6(1):100571. (PMID: 33665484) Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):858-865. (PMID: 29485063) Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):994-1002. (PMID: 19619961) Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1477-85. (PMID: 19879701) Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):444-53. (PMID: 17513063) Lancet Oncol. 2019 Nov;20(11):1531-1543. (PMID: 31540791) Radiother Oncol. 2015 Nov;117(2):277-82. (PMID: 26476560) Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22. (PMID: 2032882) J Urol. 2014 Dec;192(6):1650-6. (PMID: 24931803) Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):976-985. (PMID: 28209443) Am J Clin Oncol. 2018 Feb;41(2):115-120. (PMID: 26523442) Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1297-308. (PMID: 16029785) Nat Rev Urol. 2013 Oct;10(10):565-79. (PMID: 24018567) J Clin Oncol. 2018 Oct 10;36(29):2943-2949. (PMID: 30106637) Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):407-21. (PMID: 12023146) JAMA Netw Open. 2019 Feb 1;2(2):e188006. (PMID: 30735235) Clin Transl Radiat Oncol. 2021 Sep 15;31:34-41. (PMID: 34604551) J Clin Oncol. 2017 Jun 10;35(17):1884-1890. (PMID: 28296582) Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):454-464. (PMID: 27084660) Lancet Oncol. 2016 Aug;17(8):1061-1069. (PMID: 27339116) Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1013-5. (PMID: 15519768) Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):778-789. (PMID: 30959121) J Clin Oncol. 2017 Jun 10;35(17):1891-1897. (PMID: 28355113) J Clin Oncol. 2011 Jan 10;29(2):235-41. (PMID: 21135285) |
| فهرسة مساهمة: | Keywords: Intensity modulated proton therapy; Prostate cancer; Proton therapy; Stereotactic ablative radiotherapy; Stereotactic body radiotherapy |
| تواريخ الأحداث: | Date Created: 20240603 Latest Revision: 20240604 |
| رمز التحديث: | 20240604 |
| مُعرف محوري في PubMed: | PMC11137510 |
| DOI: | 10.1016/j.ijpt.2024.100015 |
| PMID: | 38827121 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2331-5180 |
|---|---|
| DOI: | 10.1016/j.ijpt.2024.100015 |